Characteristics of patients co-infected with HIV at the time of inpatient tuberculosis treatment initiation in Yaoundé, Cameroon: a tertiary care hospital-based cross-sectional study

Archives of Public Health

Sinata Koulla-Shiro⁷  Hermine Abessolo⁷  Roselyne Toby⁷  Jean Jacques N Noubiap²  Gabriel L Ekali¹  Mathurin Cyrille Tejiokem⁵  Serges Clotaire Billong¹  Claudia S Plottel⁴  Jean Joel R Bigna⁶  Ako A Agbor³ 

[1]National AIDS Control Committee, Ministry of Public Health, Yaoundé, Cameroon

[2]Medical Diagnostic Center, Yaounde, Cameroon

[3]Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon

[4]Department of Medicine, New York University School of Medicine, New York, USA

[5]Department of Epidemiology and Public Health, Centre Pasteur du Cameroun, Member of International Network of the Pasteur Institutes, Garoua, Cameroon

[6]Goulfey Health District, Goulfey, Cameroon

[7]Infectious Diseases Unit, Yaoundé Central Hospital, Yaoundé, Cameroon

关键词: TB;    Co-morbidities;    Resource-limited setting;    HIV co-infection;    TB &;    Profile;    Cameroon;    HIV;    AIDS;    Tuberculosis;   

Others  :  1180710
DOI  :  10.1186/s13690-015-0075-y

 received in 2014-12-10, accepted in 2015-03-07,  发布年份 2015

【 摘 要 】

Background

Knowledge of the characteristics of patients co-infected with tuberculosis (TB) and human immunodeficiency virus (HIV) when TB treatment is initiated would allow clinicians to improve care and help policy-makers develop relevant and realistic guidelines. The aim of this study was to describe socio-demographic, clinical, and laboratory characteristics of TB/HIV co-infected patients starting inpatient TB treatment in Yaoundé, Cameroon.

Methods

We conducted a retrospective cross-sectional study, collecting data from medical records of HIV-infected patients with TB, aged 15 years old or more, hospitalized in the Infectious Diseases Unit of the Yaoundé Central Hospital, Cameroon from January 1, 2006 to June 30, 2013.

Results

The mean age of 337 patients meeting study inclusion criteria was 39.3 years. More than half were female (53.4%). Most (89.3%) resided in urban areas, 44.2% had a secondary education, and 46.0% were married. The majority was receiving co-trimoxazole prophylaxis (79.5%), and two thirds were taking antiretroviral therapy (67.4%). The mean duration of known HIV infection before TB treatment was 8.4 months. Most (88.1%) had newly diagnosed TB, rather than relapsed disease. Smear-positive pulmonary TB was documented in a third, (35.3%). Laboratory data revealed a median white blood cell count of 5,100 cells/mm³ (IQR 3,300-7,990 cells/mm³), a median hemoglobin level of 8 g/dl (IQR 7–10 g/dl), and a median CD4 cell count of 102 cells/mm³ (IQR 33–178 cells/mm³). Sex differences in our study included older age in the men (p < 0.001), more of whom were married (p < 0.001) and had achieved a higher level of education (p = 0.042). Men had fewer diagnoses of smear-positive pulmonary TB (p = 0.020). They weighed more than the women (p = 0.001) and had higher hemoglobin levels (p = 0.003).

Conclusions

Suboptimal adherence to WHO treatment recommendations in our Cameroonian study reinforces the importance of prescribing co-trimoxazole in HIV infection and ART for all TB/HIV co-infected persons. We urge that Ministries of Health continue implementing and disseminating guidelines for management of TB/HIV co-infected patients, and we call for measures ensuring that healthcare facilities’ stocks of ART and co-trimoxazole are sufficient to meet the need for both.

【 授权许可】

   
2015 Agbor et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]World Health Organization. Global tuberculosis report 2013 [http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf]
• [2]Dokubo EK, Baddeley A, Pathmanathan I, Coggin W, Firth J, Getahun H, et al.: Provision of antiretroviral therapy for HIV-positive TB patients - 19 countries, Sub-Saharan africa, 2009–2013. MMWR Morbidity and Mortality Weekly Report 2014, 63(47):1104-7.
• [3]World Health Organization: Global tuberculosis control: WHO report 2011 [http://apps.who.int/iris/bitstream/10665/44728/1/9789241564380_eng.pdf?ua=1]
• [4]Programme National de lutte contre la Tuberculose: Plan stratégique de lutte contre la tuberculose au Cameroun 2015–2019 [http://www.pnlt.cm/index.php/documentation/plan-strategique-national/doc_download/18-plan-strategique-natinal-tuberculose-cameroun]
• [5]National Institute of Statistics, Ministry of Economy and Planning of Cameroon, Ministry of Public Health of Cameroon: The 2011 Cameroon Demographic and Health Survey and Multiple Indicators Cluster Survey (DHS-MICS 2011) [http://slmp-550-104.slc.westdc.net/~stat54/downloads/EDS-MICS/EDSMICS2011.pdf]
• [6]Pefura Yone EW, Kuaban C, Kengne AP: HIV testing, HIV status and outcomes of treatment for tuberculosis in a major diagnosis and treatment centre in Yaoundé, Cameroon: a retrospective cohort study. BMC Infectious Diseases 2012, 12:190. BioMed Central Full Text
• [7]Kuaban C, Bercion R, Koulla-Shiro S: HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti tuberculosis treatment in Yaoundé, Cameroon. East Afr Med J 1997, 74:474-7.
• [8]Pefura EW, Kuaban C, Kengne AP: HIV testing, HIV status and outcomes of treatment for tuberculosis in a major diagnosis and treatment centre in Yaoundé, Cameroon: a retrospective cohort study. BMC Infect Dis 2012, 12:190. BioMed Central Full Text
• [9]Programme National de lutte contre la Tuberculose. Guide pour les personnels de santé [http://www.pnlt.cm/index.php/documentation/rapports-d-activites/cat_view/4-guidetechnique?orderby=dmdatecounter&ascdesc=DESC]
• [10]World Health Organization. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance: African Region [http://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf]
• [11]Rubin D, Schenker N: Multiple imputation in health-care databases: an overview and some applications. Statistics in Medicine 1991, 10(4):585-98.
• [12]Little RJA, Rubin DB: Statistical analysis with missing data. John Wiley & Sons, New York; 1987.
• [13]Rajasekaran S, Mahilmaran A, Annadurai S, Kumar S, Raja K: Manifestation of tuberculosis in patients with human immunodeficiency virus: a large Indian study. Annals of Thoracic Medicine 2007, 2(2):58-60.
• [14]Kamath R, Sharma V, Pattanshetty S, Hegde MB, Chandrasekaran V: HIV-TB coinfection: Clinico-epidemiological determinants at an antiretroviral therapy center in Southern India. Lung India 2013, 30(4):302-6.
• [15]Mohamad Z, Niang N: Characteristics of HIV-infected tuberculosis patients in Kota Bharu Hospital, Kelantan from 1998–2001. Southeast Asia J Trop Med Public Health 2004, 35(1):140-3.
• [16]Sileshi B, Deyessa N, Girma B, Melese M, Suarez P: Predictors of mortality among TB-HIV Co-infected patients being treated for tuberculosis in Northwest Ethiopia: a retrospective cohort study. BMC Infectious Diseases 2013, 13(1):297. BioMed Central Full Text
• [17]UNAIDS: Global Report. UNAIDS report on the global AIDS epidemic 2013 [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf]
• [18]ICF International. HIV Prevalence Estimates from the Demographic and Health Surveys [http://dhsprogram.com/pubs/pdf/OD65/OD65.pdf]
• [19]Addo MM, Altfeld M: Sex-based differences in HIV type 1 pathogenesis. The Journal of Infectious Diseases 2014, 209(Suppl 3):S86-92.
• [20]van Lunzen J, Altfeld M: Sex differences in infectious diseases-common but neglected. The Journal of Infectious Diseases 2014, 209(Suppl 3):S79-80.
• [21]Yi TJ, Shannon B, Prodger J, McKinnon L, Kaul R: Genital immunology and HIV susceptibility in young women. Am J Reprod Immunol 2013, 69(Suppl 1):74-9.
• [22]Rwenge JR: Sexual behavioral among adolescents and young people in Subsaharan Africa and related factors. African Journal of Reproductive Health 2013, 17(1):49-66.
• [23]Ismail I, Bulgiba A: Predictors of death during tuberculosis treatment in TB/HIV co-infected patients in Malaysia. PLoS One 2013, 8(8):e73250.
• [24]Domingos MP, Caiaffa WT, Colosimo EA: Mortality, TB/HIV co-infection, and treatment dropout: predictors of tuberculosis prognosis in Recife, Pernambuco State, Brazil. Cad Saude Publica 2008, 24(4):887-96.
• [25]Mungrue K, Beharry A, Kalloo J, Mahabir S, Maraj T, Ramoutar R, et al.: Trends in HIV/TB coinfection in Trinidad and Tobago for the period 1998–2007. J Int Assoc Physicians AIDS Care (Chic) 2009, 8(3):170-5.
• [26]Shaweno D, Worku A: Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study. BMC Research Notes 2012, 5:682. BioMed Central Full Text
• [27]Deribe K, Yami A, Deribew A, Mesfin N, Colebunders R, Van Geertruyden JP, et al. Predictors of mortality among tuberculosis-HIV-coinfected persons in Southwest Ethiopia: a case–control study. J Int Assoc Prov AIDS Care. 2013. doi:10.1177/2325957413500528
• [28]Esmael A, Tsegaye G, Wubie M, Endris M: Tuberculosis and human immune deficiency virus Co-infection in debre Markos referral hospital in Northwest Ethiopia: a five years retrospective study. J AIDS Clin Res 2013, 4(12):263.
• [29]Sebsibe T, Takele T: HIV co-infection among tuberculosis patients in Dabat, northwest Ethiopia. J Infect Dis Immun 2013, 5(3):29-32.
• [30]Chang-Hoon L, Ji-young H, Dae-Kyu O, Mee-Kyung K, Eunjung O, Jung-wook A, et al.: The burden and characteristics of tuberculosis/human immunodeficiency virus (TB/HIV) in South Korea: a study from a population database and a survey. BMC Infect Dis 2010, 10:66. BioMed Central Full Text
• [31]Burman W, Jones B: Clinical and radiographic features of HIV-related tuberculosis. Semin Respir Infect 2003, 18:263-71.
• [32]Perfura-Yone EW, Kengne AP, Balkissou AD, Onana IN, Endale LMM, Amadou D, et al.: Clinical forms and determinants of different locations extra-pulmonary tuberculosis in an African country. Indian J Tuberc 2013, 60:107-13.
• [33]Yone EW, Kengne AP, Moifo B, Kuaban C: Prevalence and determinants of extrapulmonary involvement in patients with pulmonary tuberculosis in a Sub-Saharan African country: a cross-sectional study. Scand J Infect Dis 2013, 45(2):104-111.
• [34]Horo K, Anon JC, Achi V: Tuberculose extrapulmonaire au centre antituberculeux d’Adjame -Cote d’Ivoire. Rev Pneumol Trop 2011, 15:59-68.
• [35]de-Noronha AL, Bafica A, Nogueira L, Barral A, Barral-Netto M: Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production. Pathol Res Pract 2008, 204:155-61.
• [36]Lillebaek T, Dirksen A, Vynnycky E, Baess I, Thomsen VO: Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactivation occurring decades after the initial infection. J Infect Dis 2003, 188:1032-9.
• [37]Semba RD, Darnton-Hill I, de Pee S: Addressing tuberculosis in the context of malnutrition and HIV coinfection. Food and Nutrition Bulletin 2010, 31(4):S345-64.
• [38]Njozing NB, Miguel SS, Tih PM, Hurtig AK: Assessing the accessibility of HIV care packages among tuberculosis patients in the Northwest Region, Cameroon. BMC Public Health 2010, 10:129. BioMed Central Full Text
• [39]Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, Srinak C, et al.: Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect Dis 2009, 15(2):258-64.
• [40]Husain AN: Lung. In Robbins Basic Pathology. 9th edition. Edited by Kumar V, Abbas AK, Aster JC. Elsevier Saunders, USA; 2012:486-504.
• [41]Morfeldt-Månson L, Bo¨ttiger B, Nilsson B, von Stedingk L: Clinical signs and laboratory markers in predicting progression to AIDS in HIV-1 infected patients. Scand J Infect Dis 1991, 23:443.
• [42]Cleveland R, Liu Y: CD4 expression by erythroid precursor cells in human bone marrow. Blood 1996, 87:2275.
• [43]Walker BR, Colledge NR, Ralston SH, Penman I: Davidson’s principles and practice of medicine. 22nd edition. Elsevier Health Sciences, UK; 2013.
• [44]Rizzardi GP, Pantaleo G: The immunopathogenesis of HIV-sa1 infection. In Infectious diseases. Edited by Armstrong D, Cohen J. Harcourt, London, UK; 1999:1-12.
• [45]Day JH, Grant AD, Fielding KL, Morris L, Moloi V, Charalambous S, et al.: Does tuberculosis increase HIV load? The Journal of Infectious Diseases 2004, 190(9):1677-84.
• [46]Aaron L, Saadoun D, Calatroni I, Launay O, Memain N: Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect 2004, 10:388-98.